By exploiting the advantages of our boron chemistry platform, we have discovered and advanced into clinical development several novel and proprietary boron-based product candidates that address attractive market opportunities.

[ View pipeline ]

January 28, 2010 | Anacor To Present Preclinical Data On Orally Active Pde4 Inhibitor At The 8th Cytokines And Inflammation Conference

January 11, 2010 | Anacor To Present At J.P. Morgan Healthcare Conference

November 17, 2009 | Anacor Initiates Phase I Clinical Development For AN3365 – A Novel Antibiotic For The Treatment Of Gram-negative Infections

[ View all news ]